MARKET

VCYT

VCYT

Veracyte
NASDAQ
25.31
-0.39
-1.50%
Opening 13:28 12/07 EST
OPEN
25.67
PREV CLOSE
25.69
HIGH
25.70
LOW
25.22
VOLUME
198.19K
TURNOVER
0
52 WEEK HIGH
32.40
52 WEEK LOW
19.52
MARKET CAP
1.85B
P/E (TTM)
-36.7645
1D
5D
1M
3M
1Y
5Y
Veracyte: Statement of changes in beneficial ownership of securities
Press release · 2d ago
Health Care Sector Update for 12/04/2023: ABSI, AZN, VCYT, CI, XLV, IBB
NASDAQ · 3d ago
Weekly Report: what happened at VCYT last week (1127-1201)?
Weekly Report · 3d ago
Veracyte's Percepta Nasal Swab Test To Assess Lung Cancer Risk With Accuracy
NASDAQ · 11/29 14:17
Clinical Validation Data Published In CHEST Demonstrate That Veracyte's Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment For Patients With Lung Nodules
Veracyte's percepta nasal swab test determines lung cancer risk among current and former smokers with lung nodules. Lung cancer is the leading cause of cancer death worldwide. The non-invasive genomic test is designed to help physicians guide next steps for patients.
Benzinga · 11/29 13:35
Weekly Report: what happened at VCYT last week (1120-1124)?
Weekly Report · 11/27 10:11
Veracyte's Strategic Growth Amid Volatility And Evolution In Genomic Diagnostics
Veracyte's q3 2023 performance shows a robust 19% yoy revenue growth, driven by an increase in testing revenue and test volume. Financial health is strong with a high current ratio, positive operational cash flow, and low likelihood of needing additional financing. Veracyte is a genomic diagnostics company with strong growth potential against competitive, volatile biotech sector and regulatory challenges.
Seeking Alpha · 11/22 09:46
Weekly Report: what happened at VCYT last week (1113-1117)?
Weekly Report · 11/20 10:11
More
About VCYT
Veracyte, Inc. is a global diagnostics company. The Company is engaged in the development and commercialization of diagnostic products and biopharmaceutical services. It offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. It also offers an Immunogram, which provides an understanding of the tumor immune microenvironment by integrating data from a variety of genomic, transcriptomic, and proteomic platforms. Its tests in the United States are serviced through its own CLIA-certified laboratories in South San Francisco and San Diego, California and Austin, Texas. It also offers customized biomarker testing and analytical services.

Webull offers Veracyte Inc stock information, including NASDAQ: VCYT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VCYT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VCYT stock methods without spending real money on the virtual paper trading platform.